CAR T cell therapy shows long-lasting remissions in non-Hodgkin’s lymphoma patients

The New England Journal of Medicine published these data today. Among 28 patients who received the therapy in the single-site pilot trial after their cancers had come back following standard treatments, 43 percent of DLBCL patients achieved complete remission, as did 71 percent of patients with follicular lymphoma, the second most common form of the disease. All patients who were in remission at six months are still in remission, after a median follow-up of 28.6 months.

“Taken together, our data from both trials show that most patients who are in remission at three months stay in remission,” said Schuster, who is the Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research in the Perelman School of Medicine and director of the Lymphoma Program at the Abramson Cancer Center.

Source: https://www.news-medical.net/news/20171211/CAR-T-cell-therapy-shows-long-lasting-remissions-in-non-Hodgkins-lymphoma-patients.aspx

Advertisements

#ASH17: The big loser in CAR-T, Juno is making a bid to seize the fast lane to frontrunner status – ENDPOINTS NEWS

Juno Therapeutics may have lost the initial race for FDA approval of CAR-T (to Novartis and Gilead [Kite]), but they are preparing to demonstrate at December’s ASH 17 conference (American Society of Hematology), that theirs is the superior CAR-T therapy:

The analogy I’ll give you,” says R&D chief Sunil Agarwal: “Small changes in the antibody world can make big differences; all CARs are not the same… I think these data continue to support a best-in-class profile.”

https://endpts.com/the-big-loser-in-car-t-juno-is-making-its-bid-to-seize-the-fast-lane-to-frontrunner-status/

(FYI, The CAR-T therapy I underwent at MSK in 2015 was in partnership with Juno, although the protocol was not JCAR017)

Mayo Clinic to Offer CAR T-Cell Therapy for Relapsed Non-Hodgkin Lymphoma

October 31, 2017  Newswise — ROCHESTER, Minn. – Mayo Clinic announced today that its Rochester campus is one of 16 cancer centers nationally selected to provide chimeric antigen receptor T-cell therapy (CAR T-cell therapy) for adults with B-cell non-Hodgkin lymphoma who have not responded to, or have relapsed, after two or more lines of treatment. The therapy, called axicabtagene ciloleucel (Yescarta), is approved to treat subtypes of lymphoma, including diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma arising from follicular lymphoma, and high-grade B-cell lymphoma.

Full article: http://www.newswise.com/articles/mayo-clinic-to-offer-car-t-cell-therapy-for-relapsed-non-hodgkin-lymphoma

Novartis asks FDA to expand Kymriah’s use against blood cancer

The logical next step in the evolution of CAR-T has occurred. Novartis’ Kymriah has already been approved for leukemia, while Gilead’s (originally Kite’s) Yescarta has been approved for diffuse large B-cell lymphoma (DLBCL). Now Novartis has filed for approval of Kymriah for DLBCL as well:

http://www.reuters.com/article/us-novartis-kymriah/novartis-asks-fda-to-expand-kymriahs-use-against-blood-cancer-idUSKBN1D00QR